According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other research firms have also recently commented on GNCA. Needham & Company LLC cut their target price on shares of Genocea Biosciences from $7.00 to $6.00 and set a buy rating for the company in a research note on Thursday, February 11th. SVB Leerink upped their price objective on shares of Genocea Biosciences from $5.00 to $6.00 and gave the company an outperform rating in a research note on Tuesday.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Wednesday, February 10th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). As a group, sell-side analysts expect that Genocea Biosciences will post -0.96 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of Genocea Biosciences in the 3rd quarter worth approximately $33,000. Renaissance Technologies LLC lifted its holdings in Genocea Biosciences by 87.8% during the 4th quarter. Renaissance Technologies LLC now owns 395,763 shares of the biotechnology company’s stock worth $958,000 after buying an additional 185,069 shares in the last quarter. Personal Capital Advisors Corp acquired a new stake in Genocea Biosciences during the 4th quarter worth approximately $36,000. Finally, GSA Capital Partners LLP acquired a new stake in Genocea Biosciences during the 4th quarter worth approximately $316,000. Hedge funds and other institutional investors own 53.78% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Featured Article: Dividend Kings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.